Solid Biosciences Raises $240M

Solid Biosciences secured approximately $240 million in a private placement expected to close around March 9, 2026. The deal involves selling 14,973,257 common shares at $5.61 each and offering pre-funded warrants for up to 27,807,482 shares at $5.609 each. These warrants have an exercise price of $0.001 per share and are immediately exercisable. The financing will support pipeline development, business development, working capital, and general corporate purposes. Joint lead placement agents include Leerink Partners and Citigroup, with Cantor acting as co-lead placement agent. Truist and H.C. Wainwright & Co. are serving as co-placement agents. Key institutional investors in this round include Perceptive Advisors, Bain Capital Life Sciences, RA Capital Management, Invus, Vestal Point Capital, Janus Henderson Investors, and Deep Track Capital. Following the announcement, Solid Biosciences' shares climbed 14%. However, the stock has a beta of 2.76, indicating significant volatility. Solid Biosciences was founded in 2013 by Ilan Ganot, Andrey Zarur, and Gilad Hayeem after Ganot's son was diagnosed with Duchenne muscular dystrophy (DMD) in 2012. The company focuses on precision genetic medicines for neuromuscular and cardiac diseases. Their lead candidate, SGT-003, targets DMD, and the FDA has agreed to the design of its Phase 3 clinical trial, IMPACT DUCHENNE. Solid Biosciences is also developing SGT-212 for Friedreich's ataxia, SGT-501 for catecholaminergic polymorphic ventricular tachycardia (CPVT), and SGT-601 for TNNT2-mediated dilated cardiomyopathy. They have a collaboration with Mayo Clinic to develop AAV gene therapy platforms for cardiac diseases. As of January 9, 2026, 33 participants have been dosed in the Phase 1/2 INSPIRE DUCHENNE clinical trial. The Duchenne Muscular Dystrophy (DMD) treatment market is projected to reach $19.18 billion by 2034, exhibiting a CAGR of 17.1%. This reflects increasing diagnostic accuracy, early genetic screening, and growing awareness. While there is currently no cure for DMD, available treatments aim to slow disease progression and manage symptoms. Solid Biosciences has 127 employees. The company's EPS stands at -2.51, with an operating margin median of -878.51% and a net margin median of -796.15%.